Skip to Content


In the US, Edaravone (edaravone systemic) is a member of the drug class miscellaneous central nervous system agents and is used to treat Amyotrophic Lateral Sclerosis.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Free oxygen radical scavenger

Chemical Name

3-metyl-1-phenyl-2-pyrazolin-5-one (WHO)

Foreign Names

  • Edaravonum (Latin)
  • Edaravon (German)
  • Édaravone (French)
  • Edaravona (Spanish)

Generic Names

  • Edaravone (OS: JAN)
  • BRN 0609575 (IS)
  • MCI-186 (IS)
  • Norphenazone (IS)
  • UNII-S798V6YJRP (IS)
  • Edaravone (PH: JP XVI)

Brand Names


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.